The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GRAL | +36.49% | N/A | N/A | +285% |
| S&P | +15.57% | +80.16% | +12.49% | +27% |
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
The market took a more positive view on the company's prospects today, and there's still an opportunity, however small, for the Galleri trial to prove out.
A large clinical trial of the company's cancer screening test did not produce the desired result.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $43.60M | 14.0% |
| Gross Profit | -$11,136.00K | 30.3% |
| Gross Margin | -25.54% | 16.2% |
| Market Cap | $3.34B | 456.3% |
| Market Cap / Employee | $3.34M | 0.0% |
| Employees | 1K | 0.0% |
| Net Income | -$99,176.00K | -2.2% |
| EBITDA | -$85,503.00K | 12.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $249.73M | 16.6% |
| Accounts Receivable | $18.30M | -9.9% |
| Inventory | 16 | -14.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $43.15M | -21.4% |
| Short Term Debt | $11.72M | -11.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.47% | 39.2% |
| Return On Invested Capital | -77.62% | -0.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$63,629.00K | 39.7% |
| Operating Free Cash Flow | -$63,785.00K | 31.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.35 | 0.75 | 0.92 | 1.38 | 503.36% |
| Price to Sales | 6.70 | 13.71 | 15.06 | 23.68 | 391.68% |
| Price to Tangible Book Value | 1.78 | 4.21 | 5.40 | 8.72 | 689.10% |
| Enterprise Value to EBITDA | -2.33 | -14.01 | -19.17 | -30.83 | -3451.33% |
| Return on Equity | -62.2% | -17.7% | -16.8% | -16.1% | -75.62% |
| Total Debt | $64.32M | $62.16M | $58.59M | $54.86M | -19.49% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
